Lots of interesting abstracts and cases were submitted for TCTAP 2023. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-084
The Risk of Cardiovascular Disease in Patients With Benign Prostate Hyperplasia on 5-Alpha Reductase Inhibitors Treatment: A Meta-Analysis
By Ketut Angga Aditya Putra Pramana, Akhmad Sandy Sauqy, Yusra Pintaningrum
Presenter
Ketut Angga Aditya Putra Pramana
Authors
Ketut Angga Aditya Putra Pramana1, Akhmad Sandy Sauqy2, Yusra Pintaningrum1
Affiliation
Mataram University, Indonesia1, Bhayangkara Mataram Hospital, Indonesia2
View Study Report
TCTAP A-084
Others (Unclassified)
The Risk of Cardiovascular Disease in Patients With Benign Prostate Hyperplasia on 5-Alpha Reductase Inhibitors Treatment: A Meta-Analysis
Ketut Angga Aditya Putra Pramana1, Akhmad Sandy Sauqy2, Yusra Pintaningrum1
Mataram University, Indonesia1, Bhayangkara Mataram Hospital, Indonesia2
Background
Therapy of 5-alpha-reductase inhibitors (5ARIs) are used for the treatment of benign prostate hyperplasia (BPH). 5ARIs reduce prostate size by lowering levels of dihydrotestosterone, an androgen which promotes prostate growth. Many studies have evaluated the risk of cardiovascular disease (CVD) associated with 5ARIs therapy in patients with BPH. However, no consistent evidence of a significant association between 5ARIs therapy and CVD risk has been found. Some studies suggest that 5ARIs therapy may be associated with a higher CVD risk, but others studies have contradicted this.
Methods
We performed a systematic search in databases (PubMed, GoogleScholar, ScienceDirect,and Cochrane Library) from January 2010 to July 2022. We searched for original research articles that included patients with BPH who treated with 5ARIs treatment compared with control or no medication. The articles then assessed for relevancy and quality assessment. Review Manager 5.4.1 was utilized to compute the summary of Odss Ratio(OR) and 95% CI for the outcomes.
Results
We identified three observationalstudies involving 131,105 patients with BPH and 22.95% of the study subjects received5ARIs treatment. Pooled analysis showedthat BPH patients on 5ARI treatment had higher risk for CVD compared with control [OR 1.13 (95% CI 1.07 - 1.18; p<0.00001)].
Conclusion
In general, this meta-analysis shows that 5ARIs treatment significantly increases the risk for CVD in patients with BPH. Regarding this result, further mechanistic research is needed.